The SGLT2 Inhibitors Market size was valued at USD 16.90 billion in 2024 and is expected to reach USD 29.73 billion by 2032, growing at a CAGR of 7.33% over the forecast period of 2025-2032.
To Get more information on SGLT2 Inhibitors Market - Request Free Sample Report
The rising global type 2 diabetes burden and growing acceptance of novel medicines are driving the strong expansion of the SGLT2 inhibitors market. The International Diabetes Federation estimates that 783 million adults worldwide will have diabetes by 2045, which emphasizes the critical necessity of efficient treatment solutions. A major health concern in the U.S. is type 2 diabetes.
For instance, type 2 diabetes accounts for nearly 90% of all diabetics. The recent CDC statistics (2021–2023) show that around 15.8% of U.S. adults have diabetes; of these, 4.5% are undiagnosed cases and 11.3% are diagnosed cases. Men (18.0%) have a somewhat greater diabetes prevalence than women (13.7%). From 9.7% in 2000 to 15.8% in 2023, the prevalence of diabetes among American adults has surged.
Governments are reacting with more awareness campaigns and early diagnosis and management investments, therefore boosting the SGLT2 inhibitors market growth. The U.S. SGLT2 inhibitors market size was valued at USD 5.12 billion in 2024 and is expected to reach USD 8.96 billion by 2032 with a CAGR of 7.25%. Strong insurance coverage and healthcare infrastructure, as well as the FDA's enlarged approvals for SGLT2 inhibitor drugs in indications outside of diabetes, including heart failure and chronic renal disease, help to support this dominance. These government-backed projects and regulatory developments are key drivers influencing SGLT2 inhibitors market trends and supporting ongoing market expansion.
The SGLT2 inhibitors market analysis reveals that the market is characterized by significant technological developments, major R&D expenditure, and an increasing focus on complete disease management solutions.
Drivers
Rising Type 2 Diabetes and Cardiovascular Diseases Accelerate SGLT2 Inhibitor Demand Globally
The main driver behind the SGLT2 inhibitors market growth is the rising global load of type 2 diabetes and cardiovascular illnesses. With over 537 million people affected by diabetes in 2021 and projections indicating a rise to 783 million by 2045, the need for effective glycemic control therapies is surging. SGLT2 inhibitors were originally designed for the treatment of diabetes, showing great advantages in controlling chronic renal disease and lowering the risk of hospitalization for heart failure, hence extending their clinical relevance. Furthermore, boosting their inclusion into standard treatment procedures, the American Diabetes Association's 2025 recommendations support SGLT2 inhibitors as first-line therapy for type 2 diabetes with concomitant cardiovascular diseases.
Healthcare systems are progressively using SGLT2 inhibitors as a preferred therapeutic choice as aging populations, inactive lifestyles, and poor diets drive up the occurrence of these chronic diseases. As governments and health organizations give creative ideas top priority to solve the increasing social and financial weight of chronic diseases, this broad therapeutic influence guarantees continuous growth in both developed and developing markets.
Restraints
Safety Issues and Competition from Established Diabetes Treatments Restrict the SGLT2 Inhibitors Market Growth
The SGLT2 inhibitor market faces intense competition from other well-known groups of diabetic drugs, including metformin, sulfonylureas, DPP-4 inhibitors, and GLP-1 receptor agonists. Many healthcare professionals and payers choose these substitutes because they are often more reasonably priced and have a longer history of safety and effectiveness. Furthermore, discouraging prescribers and patients from using these newer treatments are worried about possible side effects of SGLT2 inhibitors, including urinary tract infections, dehydration, and rare but major hazards, including amputations. Particularly in markets needing large amounts of local clinical data, regulatory obstacles impede entrance and expansion and slow down the rate at which SGLT2 inhibitors can become accepted as a standard of care.
By Drug
The Jardiance (empagliflozin) segment dominated the SGLT2 inhibitors market with a 51% global diabetes treatment market share in 2024 and is predicted to rise with a notable CAGR over the forecast period. Major clinical studies such as the EMPA-KIDNEY research, which revealed a 28% decrease in chronic kidney disease progression or cardiovascular death, have shown Jardiance's proven efficacy in lowering cardiovascular and renal risks, therefore attesting to this leadership. Regulatory approvals for the use of SGLT2 inhibitors in treating heart failure and chronic kidney disease driven by positive cardiovascular outcomes are further expanding their market reach.
Reflecting Jardiance's strong safety and effectiveness profile, the FDA and European Commission have extended the label to include pediatric type 2 diabetes and chronic renal disease.
For instance, the FDA approved Jardiance for children ten years of age and above with type 2 diabetes in June 2023, and in April 2022, Japan's PMDA approved its usage for heart failure with preserved ejection fraction.
By Indication
With 72% of the SGLT2 inhibitors market share in 2024, the Type 2 Diabetes segment led the market. Demand for efficient treatments has been spurred by the increasing diabetes prevalence, with around 783 million adults expected to be afflicted by 2045. Reflecting revised guidelines from the ADA, EASD, and ESC, SGLT2 inhibitors market trends suggest that these medications are given as first-line or add-on therapy for patients with high cardiovascular or renal risk, more and more. Early intervention and access to creative treatments are further supported by government programs such as the National Diabetes Prevention Program of the U.S. CDC.
The cardiovascular segment is expected to grow with the fastest CAGR in the SGLT2 inhibitors market growth over the forecast period. Driven by widening approvals for SGLT2 Inhibitors for Heart Failure and shown declines in major adverse cardiovascular events and heart failure hospitalizations.
For instance, in May 2023, the FDA approved Lexicon Pharmaceuticals sotagliflozin, a dual SGLT1/2 inhibitor, for heart failure, significantly advancing Cardiovascular Outcomes with SGLT2 Inhibitors.
The EMPA-KIDNEY trial and revised ESC recommendations have strengthened the case for SGLT2 inhibitors in treating chronic kidney disease and heart failure, therefore extending the Sodium-Glucose Cotransporter-2 Inhibitors Market beyond traditional diabetic treatment.
By Distribution Channel
Hospital pharmacies maintained a dominance with 51% of the SGLT2 inhibitors market share in 2024, reflecting the complexity of treatment demanded for patients with numerous comorbidities. Particularly for patients with advanced disease or those under careful observation, the SGLT2 inhibitors market analysis reveals that integrated care models in hospitals help to increase adoption rates by means of payment policies.
For instance, government initiatives in the U.S. and the United Kingdom guarantee coverage for SGLT2 inhibitors recommended in hospital environments, therefore generating ongoing demand.
The online pharmacies segment is expected to see the fastest CAGR of 7.89% over the forecast period. Driven by digital health use, telemedicine integration, and home delivery convenience, using digital health regulations, nations such as India are increasing access to SGLT2 inhibitors in rural and underdeveloped areas, therefore demonstrating how SGLT2 inhibitor firms are changing to fit changing patient demands and market dynamics. Rising e-prescriptions and virtual consultations should help this segment even more, particularly in the management of chronic diseases.
The North America region dominated the market, comprising 41% SGLT2 inhibitors share in 2024 and establishing industry norms for clinical adoption, pricing, and regulatory frameworks, driven by a great prevalence of type 2 diabetes, modern healthcare infrastructure, and early regulatory approvals for major SGLT2 inhibitor drugs, including Jardiance, Invokana, and Farxiga, the U.S. SGLT2 inhibitor market held the largest revenue share 74% of the NA region.
The growing awareness of the several advantages of SGLT2 inhibitors, including cardiovascular and renal protection, which have been included in the American Diabetes Association recommendations and generally embraced by doctors, drives this growth. With local healthcare systems and payment policies influencing adoption patterns, Canada and the rest of North America also make significant contributions.
With a CAGR of 7.86%, the Asia Pacific region is the fastest-growing region throughout the forecast period. Particularly in major nations such as China and India, the fast economic development, urbanization, and lifestyle changes in these areas have resulted in an explosion in type 2 diabetes incidence. With approximately 414 million Asians aged 65 and over in 2020, the figure is estimated to reach 1.2 billion by 2060; the aging population is a major factor. SGLT2 inhibitors, among other advanced diabetic medications, are in more demand due to this demographic change. Early diagnosis, preventive care, and better access to creative medicines are aggressively pushed by governments and healthcare institutions across the Asia Pacific.
The global SGLT2 inhibitors market held a significant share of the European region. Rising type 2 diabetes prevalence, an aging population, and a better knowledge of the cardiovascular and renal benefits of SGLT2 inhibitor drugs drive the substantial growth of the market. Supported by sophisticated healthcare infrastructure and advantageous reimbursement regulations, Western Europe, especially Germany and France, owns the highest market share. Following changing clinical guidelines, the area is seeing rising acceptance of SGLT2 inhibitors, including Invokana, Jardiance, and Farxiga, for heart failure and chronic renal disease, in addition to diabetes control.
Latin America, the Middle East, and Africa (LAMEA) are experiencing steady SGLT2 inhibitors market growth, albeit from a smaller base. Rising knowledge of diabetes and cardiovascular disease, better access to healthcare, and deliberate government projects help these areas. Rising adoption rates are being driven, for instance, by Saudi Arabia's cardiovascular health programs and Brazil's diabetes awareness campaign.
Get Customized Report as per Your Business Requirement - Enquiry Now
The key SGLT2 inhibitor companies are Boehringer Ingelheim International GmbH, Sanofi, AstraZeneca, TheracosBio, LLC, Merck & Co., Inc., TheracosBio, LLC, Glenmark Pharmaceuticals Ltd., Lexicon Pharmaceuticals, Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, and others.
The Phase 3 EMPACT-MI trial of Boehringer Ingelheim International GmbH revealed in April 2024 that Jardiance (empagliflozin) lowered the risk of hospitalization for heart failure by 10%, an outcome expected to influence future demand for the medication.
The first dual SGLT1/2 inhibitor, sotagliflozin, was approved by the FDA for heart failure in May 2023, so underlining the growing importance of SGLT2 inhibitors in cardiovascular treatment.
Eli Lilly and Boehringer Ingelheim said in September 2023 that U.S. FDA approval for Jardiance based on its efficacy in reducing the risk of cardiovascular death and hospitalization resulting from chronic kidney disease (CKD) has been granted.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 16.9 Billion |
| Market Size by 2032 | USD 29.73 Billion |
| CAGR | CAGR of 7.33% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Indication (Chronic Kidney Disease (CKD), Type 2 Diabetes, Cardiovascular, and Others) • By Drug (Jardiance (Empagliflozin), Inpefa (Sotagliflozin), Farxiga (Dapagliflozin), Invokana (Canagliflozin), Qtern (Dapagliflozin/Saxagliptin), and Others) • By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Boehringer Ingelheim International GmbH, Sanofi, AstraZeneca, TheracosBio, LLC, Merck & Co., Inc., TheracosBio, LLC, Glenmark Pharmaceuticals Ltd., Lexicon Pharmaceuticals, Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company |
Ans. The projected market size for the SGLT2 Inhibitors Market is USD 29.73 billion by 2032.
Ans: The North America region dominated the SGLT2 Inhibitors Market in 2024.
Ans. The CAGR of the SGLT2 Inhibitors Market is 7.33% during the forecast period of 2025-2032.
Ans: Safety issues and competition from established diabetes treatments restrict the growth of the SGLT2 inhibitors market
Ans: The Hospital Pharmacies segment dominated the SGLT2 Inhibitors Market.
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Prescription Trends of SGLT2 Inhibitors (2023), by Region
5.2 Production and Usage Volume of SGLT2 Inhibitor Drugs (2020–2023)
5.3 Healthcare Spending on SGLT2 Inhibitors (2023)
5.4 Regulatory Approvals and Clinical Trial Trends (2020–2023)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. SGLT2 Inhibitors Market Segmentation By Indication
7.1 Chapter Overview
7.2 Chronic Kidney Disease (CKD)
7.2.1 Chronic Kidney Disease (CKD) Market Trends Analysis (2021-2032)
7.2.2 Chronic Kidney Disease (CKD) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Type 2 Diabetes
7.3.1 Type 2 Diabetes Market Trends Analysis (2021-2032)
7.3.2 Type 2 Diabetes Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Cardiovascular
7.4.1 Cardiovascular Market Trends Analysis (2021-2032)
7.4.2 Cardiovascular Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Others
7.5.1 Others Market Trends Analysis (2021-2032)
7.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. SGLT2 Inhibitors Market Segmentation By Drug
8.1 Chapter Overview
8.2 Jardiance (Empagliflozin)
8.2.1 Jardiance (Empagliflozin) Market Trend Analysis (2021-2032)
8.2.2 Jardiance (Empagliflozin) Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Inpefa (Sotagliflozin)
8.3.1 Inpefa (Sotagliflozin) Market Trends Analysis (2021-2032)
8.3.2 Inpefa (Sotagliflozin) Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Farxiga (Dapagliflozin)
8.4.1 Farxiga (Dapagliflozin) Market Trends Analysis (2021-2032)
8.4.2 Farxiga (Dapagliflozin) Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Invokana (Canagliflozin)
8.5.1 Invokana (Canagliflozin) Market Trends Analysis (2021-2032)
8.5.2 Invokana (Canagliflozin) Market Size Estimates and Forecasts to 2032 (USD Billion)
8.6 Qtern (Dapagliflozin/Saxagliptin)
8.6.1 Qtern (Dapagliflozin/Saxagliptin) Market Trends Analysis (2021-2032)
8.6.2 Qtern (Dapagliflozin/Saxagliptin) Market Size Estimates and Forecasts to 2032 (USD Billion)
8.7 Others
8.7.1 Others Market Trends Analysis (2021-2032)
8.7.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. SGLT2 Inhibitors Market Segmentation By Distribution Channel
9.1 Chapter Overview
9.2 Hospital Pharmacies
9.2.1 Hospital Pharmacies Market Trends Analysis (2021-2032)
9.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Retail Pharmacies
9.3.1 Retail Pharmacies Market Trends Analysis (2021-2032)
9.3.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Online Pharmacies
9.4.1 Online Pharmacies Market Trends Analysis (2021-2032)
9.4.2 Online Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America SGLT2 Inhibitors Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.2.4 North America SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.2.5 North America SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.2.6.2 USA SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.2.6.3 USA SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.2.7.2 Canada SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.2.7.3 Canada SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.2.8.2 Mexico SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.2.8.3 Mexico SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe SGLT2 Inhibitors Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.3.4 Europe SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.5 Europe SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.6 Germany
10.3.6.1 Germany SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.3.6.2 Germany SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.6.3 Germany SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.3.7.2 France SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.7.3 France SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.3.8.2 UK SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.8.3 UK SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.3.9.2 Italy SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.9.3 Italy SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.3.10.2 Spain SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.10.3 Spain SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.11 Poland
10.3.11.1 Poland SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.3.11.2 Poland SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.11.3 Poland SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.12 Turkey
10.3.12.1 Turkey SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.3.12.2 Turkey SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.12.3 Turkey SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.13 Rest of Europe
10.3.13.1 Rest of Europe SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.3.13.2 Rest of Europe SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.13.3 Rest of Europe SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific SGLT2 Inhibitors Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia Pacific SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.4.4 Asia Pacific SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.5 Asia Pacific SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.4.6.2 China SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.6.3 China SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.4.7.2 India SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.7.3 India SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.4.8.2 Japan SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.8.3 Japan SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.4.9.2 South Korea SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.9.3 South Korea SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.4.10.2 Singapore SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.10.3 Singapore SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.4.11.2 Australia SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.11.3 Australia SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.12 Rest of Asia Pacific
10.4.12.1 Rest of Asia Pacific SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia Pacific SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia Pacific SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa SGLT2 Inhibitors Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.5.4 Middle East and Africa SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.5 Middle East and Africa SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.5.6.2 UAE SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.6.3 UAE SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.8 Qatar
10.5.8.1 Qatar SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.5.8.2 Qatar SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.8.3 Qatar SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.9 South Africa
10.5.9.1 South Africa SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.5.9.2 South Africa SGLT2 Inhibitors Market Estimates and Forecasts By Drug (2021-2032) (USD Billion)
10.5.9.3 South Africa SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.10 Rest of Middle East & Africa
10.5.10.1 Rest of Middle East & Africa SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.5.10.2 Rest of Middle East & Africa SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.10.3 Rest of Middle East & Africa SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America SGLT2 Inhibitors Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.6.4 Latin America SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.6.5 Latin America SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.6.6.2 Brazil SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.6.6.3 Brazil SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.6.7.2 Argentina SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.6.7.3 Argentina SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
11. Company Profiles
11.1 Boehringer Ingelheim International GmbH
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product/ Services Offered
11.1.4 SWOT Analysis
11.2 Sanofi
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product/ Services Offered
11.2.4 SWOT Analysis
11.3 AstraZeneca
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product/ Services Offered
11.3.4 SWOT Analysis
11.4 TheracosBio, LLC
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product/ Services Offered
11.4.4 SWOT Analysis
11.5 Merck & Co., Inc.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product/ Services Offered
11.5.4 SWOT Analysis
11.6 TheracosBio, LLC
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product/ Services Offered
11.6.4 SWOT Analysis
11.7 Glenmark Pharmaceuticals Ltd.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product/ Services Offered
11.7.4 SWOT Analysis
11.8 Lexicon Pharmaceuticals, Inc.
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product/ Services Offered
11.8.4 SWOT Analysis
11.9 Eli Lilly and Company
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product/ Services Offered
11.9.4 SWOT Analysis
11.10 Johnson & Johnson Services, Inc.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Indication
Chronic Kidney Disease (CKD)
Type 2 Diabetes
Cardiovascular
Others
By Drug
Jardiance (Empagliflozin)
Inpefa (Sotagliflozin)
Farxiga (Dapagliflozin)
Invokana (Canagliflozin)
Qtern (Dapagliflozin/Saxagliptin)
Others
By Distribution Channel
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Request for Segment Customization as per your Business Requirement: Segment Customization Request
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Pharmacy Benefit Management Market size was estimated at USD 553.4 billion in 2023 and is expected to reach USD 934.9 billion by 2032 at a CAGR of 6.0% during the forecast period of 2024-2032.
Medical Document Management Systems Market was valued at USD 0.63 Bn in 2023 and is expected to reach USD 1.81 Bn by 2032, growing at a CAGR of 12.48%.
The Cell Therapy Human Raw Materials Market Size was valued at USD 2.9 Bn in 2023 and will reach $18.1 Bn by 2032 and grow at a CAGR of 22.6% by 2024-2032.
The HPV Testing And Pap Test Market Size was valued at USD 4.95 Billion in 2023 and is expected to reach USD 14.31 Billion by 2032 and grow at a CAGR of 12.54% over the forecast period 2024-2032.
PARP Inhibitor Biomarkers Market was valued at USD 901.25 million in 2023 and is expected to reach USD 1892.80 million by 2032, growing at a CAGR of 8.64% from 2024-2032.
The Medical Equipment Rental Market was valued at USD 58.57 Billion in 2023 and is expected to reach USD 97.69 billion by 2032 and grow at a CAGR of 5.85%.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
